MedTrace Logo

Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer

NCT00913705 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 624

Last updated 2022-06-13

No results posted yet for this study

Summary

Open-label multicenter randomized Phase III trial.

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

DRUG

Neoadjuvant chemotherapy (taxol and carboplatin)

Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.

DRUG

Adjuvant chemotherapy (taxol and carboplatin)

Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery

PROCEDURE

Surgery

Surgery

Sponsors & Collaborators

  • Spanish Lung Cancer Group

    lead OTHER

Principal Investigators

  • Enriqueta Felip, MD · HOSPITAL VALL D'HEBRON (Barcelona)

  • Rafael Rosell, MD · ICO-HOSPITAL UNIV. GERMANS TRIAS I PUJOL (Badalona)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2007-12-31
Completion
2009-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00913705 on ClinicalTrials.gov